Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

In today’s Pharmaceutical Executive Daily, a new study reignites debate over a potential link between Tylenol use and autism ...

TopGum Industries signed a binding letter of intent to acquire U.S.-based operations manufacturing pharmaceutical products ...

AI can accelerate drug discovery, clinical development, and patient access, but regulatory hurdles remain. Anders Romare, ...

In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of ...

In today's healthcare environment, securing regulatory approval is only the beginning. The real challenge lies in ensuring ...

A new study suggests that there is no link between Tylenol and autism. More specifically, the research shows that women ...

As a result of the acquisition, Pfizer will no longer hold shares of ViiV Healthcare Limited and Shionogi will see its holdings increase to 21.7%. 1 The majority shareholder of ViiV Healthcare Limited ...

The alternative is to purchase a fit-for-purpose solution. This approach requires in-depth investigation to ensure that the ...

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

Ahead of her presentation at JP Morgan, Pharmaceutical Technology spoke with Dr. Jennifer Levin Carter, MD, founder and CEO ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...